GADD45B and hepatocellular carcinoma: In various models of immunotherapy‐resistant solid cancers, including HCC and ovarian adenocarcinoma, Gadd45β loss in bone marrow cells restores the activation of pro‐inflammatory tumour‐associated macrophages (TAMs) and tumour immune infiltration thereby reducing tumour occurrence, showing a direct relationship between elevated expression of Gadd45β and poor prognosis [32].